Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease

Tissue Antigens

Volumn 61, Issue 2, 2003, Pages 159-165

  Yoshizawa, Kaname ^a   Ota, M ^a   Saito, S ^a   Maruyama, A ^a   Yamaura, T ^a   Rokuhara, A ^a   Orii, K ^a   Ichijo, T ^a   Matsumoto, A ^a   Tanaka, E ^a   Kiyosawa, K ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Asymptomatic carrier; Hepatitis C virus; Human leukocyte antigen; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DQB1 ANTIGEN; HLA DR ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA FINGERPRINTING; ECHOGRAPHY; FEMALE; GENE LOCUS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HLA SYSTEM; HUMAN; JAPAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYMPTOM;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 12444253524     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2003.00015.x     Document Type: Article

References (29)

1. Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989: 244: 362-4.
2. Alter HJ, Purcell RH, Shih JW et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989: 321: 1494-500.
3. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990: 12: 671-5.
4. Tong MJ, El-Farra N, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Eng J Med 1995: 332: 1463-6.
5. Seeff LB, Miller RN, Rabkin CS et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Int Med 2000: 132: 105-11.
6. Di Bisceglie AM. Natural history of hepatitis C: Its impact on clinical management. Hepatology 2000: 31: 1014-8.
7. Thio CL, Thomas DL, Carrington M. Chronic viral hepatitis and the human genome. Hepatology 2000: 31: 819-27.
8. Alric L, Fort M, Izopet J et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997: 113: 1675-81.
9. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HD for the HENCORE group. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999: 354: 2119-24.
10. Fanning LJ, Levis J, Kenny-Walsh E, Wynne F, Whelton M, Shanahan F. Viral clearance in hepatitis C (1b) infection: Relationship with human leukocyte antigen class II in a homogeneous population. Hepatology 2000: 31: 1334-7.
11. Peano G, Menardi G, Ponztto A, Fenoglio LM. HLA-DR5 antigen: a genetic factor influencing the outcome of hepatitis C virus infection? Arch Int Med 1994: 154: 2733-6.
12. Kuzushita N, Hayashi N, Katayama K et al. Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels. J Med Virol 1996: 48: 1-7.
13. Aikawa T, Kojima M, Onishi H et al. HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C. J Med Virol 1996: 49: 274-8.
14. Yasunami R, Miyamoto T, Kanda T. HLA-DRB1 is related to the pathological changes of the liver in chronic hepatitis C. Hepatol Res 1997: 7: 3-12.
15. Kuzushita N, Hayashi N, Moribe T et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998: 27: 240-4.
16. Asti M, Martinetti M, Zavaglia C et al. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology 1999: 29: 1272-9.
17. Haruna Y, Miyamoto T, Yasunami R, Kanda T, Fushimi H, Katoh K. Human leukocyte antigen DRB1 1302 protects against bile duct damage and portal lymphocyte infiltration in patients with chronic hepatitis C. J Hepatol 2000: 32: 837-42.
18. Tillmann HL, Chen DF, Trautwein C et al. Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 2001: 48: 714-8.
19. Persico M, Persico E, Suozzo R et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000: 118: 760-4.
20. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infection sources. J General Virol 1992: 73: 673-9.
21. Simmonds P, McOmish F, Yap PL et al. Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J General Virol 1993: 74: 661-8.
22. Gaiani S, Gramantieri L, Venturoli N et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997: 27: 979-85.
23. Bedossa P, Poypard T for the METAVIR cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996: 24: 289-93.
24. Inoko H, Ota M. PCR-RFLP. In: Bidwell J, Hui KM, eds. Handbook of HLA Typing Techniques. Boca Raton, FL: CRC Press, 1993: 9-70.
25. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 2000: 56: 522-9.
26. Puoti C, Castellacci R, Montagnese F et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002: 37: 117-23.
27. Imanishi T, Akaza T et al. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991.2. Oxford: Oxford University Press, 1992: 1073.
28. Fu X-T, Bono CP, Woulfe SL et al. Pocket 4 of HLA-DR (α, β1: 0401) molecule is a major determinant of T cell recognition of peptide. J Exp Med 1995: 181: 915-26.
29. + T cell responses in chronically infected and non-viremic patients. Eur J Immunol 2001: 31: 1438-46.